REPORTS

Let’s Pullulate and Expand Your Business

mRNA Vaccines & Therapeutics Market - Global Professional Analysis and Forecast to 2026

Oct 12, 2019  |  167 PAGES  |  REPORT CODE: CMM207006
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide mRNA Vaccines & Therapeutics market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 2.7% during the forecast period.

This report presents the market size and development trends by detailing the mRNA Vaccines & Therapeutics market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the mRNA Vaccines & Therapeutics market will be shown in this report. In short, this report will comprehensively reveal the characteristics of mRNA Vaccines & Therapeutics industry and will help you to build a panoramic view of the industrial development.

mRNA Vaccines & Therapeutics Market, By Type:

  • In-house mRNA Manufacturing

  • Out-sourced mRNA Manufacturing

mRNA Vaccines & Therapeutics Market, By Application:

  • Cancer Vaccines

  • Infectious Disease Vaccines

  • In vivo Therapeutics

  • Gene Editing

  • Others

Some of the leading players are as follows:

  • Kernal Biologics

  • BioNTech

  • Intellia Therapeutics

  • PhaseRx

  • Moderna Therapeutics

  • CRISPR Therapeutics

  • In-Cell-Art

  • Ethris

  • Boehringer Ingelheim

  • AstraZeneca

  • Argos Therapeutics

  • Janssen

  • RaNa Therapeutics

  • GlaxoSmithKline Vaccines

  • Novartis

  • Bayer

  • Precision NanoSystems

  • ETheRNA immunotherapies

  • MaxCyte

  • CureVac

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 mRNA Vaccines & Therapeutics Market: Technology Type Analysis

  • 4.1 mRNA Vaccines & Therapeutics Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 mRNA Vaccines & Therapeutics Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 In-house mRNA Manufacturing

    • 4.3.2 Out-sourced mRNA Manufacturing

5 mRNA Vaccines & Therapeutics Market: Product Analysis

  • 5.1 mRNA Vaccines & Therapeutics Product Market Share Analysis, 2018 & 2026

  • 5.2 mRNA Vaccines & Therapeutics Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 mRNA Vaccines & Therapeutics Market: Application Analysis

  • 6.1 mRNA Vaccines & Therapeutics Application Market Share Analysis, 2018 & 2026

  • 6.2 mRNA Vaccines & Therapeutics Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Cancer Vaccines

    • 6.3.2 Infectious Disease Vaccines

    • 6.3.3 In vivo Therapeutics

    • 6.3.4 Gene Editing

    • 6.3.5 Others

7 mRNA Vaccines & Therapeutics Market: Regional Analysis

  • 7.1 mRNA Vaccines & Therapeutics Regional Market Share Analysis, 2018 & 2026

  • 7.2 mRNA Vaccines & Therapeutics Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Kernal Biologics

    • 9.1.1 Kernal Biologics Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 BioNTech

    • 9.2.1 BioNTech Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Intellia Therapeutics

    • 9.3.1 Intellia Therapeutics Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 PhaseRx

    • 9.4.1 PhaseRx Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Moderna Therapeutics

    • 9.5.1 Moderna Therapeutics Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 CRISPR Therapeutics

    • 9.6.1 CRISPR Therapeutics Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 In-Cell-Art

    • 9.7.1 In-Cell-Art Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Ethris

    • 9.8.1 Ethris Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Boehringer Ingelheim

    • 9.9.1 Boehringer Ingelheim Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 AstraZeneca

    • 9.10.1 AstraZeneca Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Argos Therapeutics

    • 9.11.1 Argos Therapeutics Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Janssen

    • 9.12.1 Janssen Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 RaNa Therapeutics

    • 9.13.1 RaNa Therapeutics Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 GlaxoSmithKline Vaccines

    • 9.14.1 GlaxoSmithKline Vaccines Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 Novartis

    • 9.15.1 Novartis Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

  • 9.16 Bayer

    • 9.16.1 Bayer Company overview

    • 9.16.2 Financial performance

    • 9.16.3 Product benchmarking

    • 9.16.4 Strategic initiatives

    • 9.16.5 SWOT analysis

  • 9.17 Precision NanoSystems

    • 9.17.1 Precision NanoSystems Company overview

    • 9.17.2 Financial performance

    • 9.17.3 Product benchmarking

    • 9.17.4 Strategic initiatives

    • 9.17.5 SWOT analysis

  • 9.18 ETheRNA immunotherapies

    • 9.18.1 ETheRNA immunotherapies Company overview

    • 9.18.2 Financial performance

    • 9.18.3 Product benchmarking

    • 9.18.4 Strategic initiatives

    • 9.18.5 SWOT analysis

  • 9.19 MaxCyte

    • 9.19.1 MaxCyte Company overview

    • 9.19.2 Financial performance

    • 9.19.3 Product benchmarking

    • 9.19.4 Strategic initiatives

    • 9.19.5 SWOT analysis

  • 9.20 CureVac

    • 9.20.1 CureVac Company overview

    • 9.20.2 Financial performance

    • 9.20.3 Product benchmarking

    • 9.20.4 Strategic initiatives

    • 9.20.5 SWOT analysis

 

The List of Tables and Figures (Totals 87 Figures and 123 Tables)

  • Figure In-house mRNA Manufacturing mRNA Vaccines & Therapeutics market, 2015 - 2026 (USD Million)

  • Figure Out-sourced mRNA Manufacturing mRNA Vaccines & Therapeutics market, 2015 - 2026 (USD Million)

  • Figure Cancer Vaccines market, 2015 - 2026 (USD Million)

  • Figure Infectious Disease Vaccines market, 2015 - 2026 (USD Million)

  • Figure In vivo Therapeutics market, 2015 - 2026 (USD Million)

  • Figure Gene Editing market, 2015 - 2026 (USD Million)

  • Figure Others market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America mRNA Vaccines & Therapeutics market, by country, 2015 - 2026 (USD Million)

  • Table North America mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table North America mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table North America mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table U.S. mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table U.S. mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Canada mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Canada mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Europe mRNA Vaccines & Therapeutics market, by country, 2015 - 2026 (USD Million)

  • Table Europe mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Europe mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Europe mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table U.K. mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table U.K. mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Germany mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Germany mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table France mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table France mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Italy mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Italy mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Spain mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Spain mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific mRNA Vaccines & Therapeutics market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table China mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table China mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Japan mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Japan mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table India mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table India mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Latin America mRNA Vaccines & Therapeutics market, by country, 2015 - 2026 (USD Million)

  • Table Latin America mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Latin America mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Latin America mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Brazil mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Brazil mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Mexico mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Mexico mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Argentina mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Argentina mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table MEA mRNA Vaccines & Therapeutics market, by country, 2015 - 2026 (USD Million)

  • Table MEA mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table MEA mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table MEA mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table South Africa mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table South Africa mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria mRNA Vaccines & Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria mRNA Vaccines & Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria mRNA Vaccines & Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Kernal Biologics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table BioNTech Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Intellia Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table PhaseRx Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Moderna Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table CRISPR Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table In-Cell-Art Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Ethris Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Boehringer Ingelheim Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Argos Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Janssen Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table RaNa Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table GlaxoSmithKline Vaccines Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novartis Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bayer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Precision NanoSystems Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table ETheRNA immunotherapies Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table MaxCyte Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table CureVac Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$4840
$9680
BUY NOWClick MeBUY NOW
top